Cardio-Oncology (Dec 2023)

Lessons learnt in the first year of an Australian pediatric cardio oncology clinic

  • Claudia Toro,
  • Ben Felmingham,
  • Mangesh Jhadav,
  • David S. Celermajer,
  • Andre La Gerche,
  • John O’Sullivan,
  • Sanjeev Kumar,
  • Marion K. Mateos,
  • Joy Fulbright,
  • Dinisha Govender,
  • Lane Collier,
  • Michael Cheung,
  • David D. Eisenstat,
  • Peter W. Lange,
  • Julian Ayer,
  • David A. Elliott,
  • Rachel Conyers

DOI
https://doi.org/10.1186/s40959-023-00194-x
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Modern oncological therapies together with chemotherapy and radiotherapy have broadened the agents that can cause cardiac sequelae, which can manifest for pediatric oncology patients while on active treatment. Recommendations for high-risk patients who should be monitored in a pediatric cardio-oncology clinic have previously been developed by expert Delphi consensus by our group. In 2022 we opened our first multidisciplinary pediatric cardio-oncology clinic adhering to these recommendations in surveillance and management. Objectives Our pediatric cardio-oncology clinic aimed to: (i) Document cardiovascular toxicities observed within a pediatric cardio-oncology clinic and. (ii) Evaluate the applicability of the Australian and New Zealand Pediatric Cardio-Oncology recommendations. Methods Monthly multidisciplinary cardio-oncology clinics were conducted in an Australian tertiary pediatric hospital. Structured standardised approaches to assessment were built into the electronic medical record (EMR). All patients underwent baseline echocardiogram and electrocardiogram assessment together with vital signs in conjunction with standard history and examination. Results Nineteen (54%) individuals had a documented cardiovascular toxicity or pre-existing risk factor prior to referral. The two most common cardiovascular toxicities documented during clinic review included Left Ventricular Dysfunction (LVD) and hypertension. Of note 3 (8.1%) patients had CTCAE grade III LVD. An additional 10 (27%) patients reviewed in clinic had CTCAE grade I hypertension. None of these patients had hypertension noted within their referral. Cascade testing for cardiac history was warranted in 2 (5.4%) of patients. Conclusions Pediatric cardio-oncology clinics are likely beneficial to documenting previously unrecognised cardiotoxicity and relevant cardiac family histories, whilst providing an opportunity to address lifestyle risk factors.

Keywords